These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38167649)

  • 1. MAD2L2, a key regulator in ovarian cancer and promoting tumor progression.
    Xu K; Zheng X; Shi H; Ou J; Ding H
    Sci Rep; 2024 Jan; 14(1):130. PubMed ID: 38167649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.
    Li L; Jiang P; Hu W; Zou F; Li M; Rao T; Ruan Y; Yu W; Ning J; Cheng F
    J Transl Med; 2024 Mar; 22(1):295. PubMed ID: 38515112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promoting effect and mechanism of MAD2L2 on stemness maintenance and malignant progression in glioma.
    Liu Z; Wang S; Yu K; Chen K; Zhao L; Zhang J; Dai K; Zhao P
    J Transl Med; 2023 Nov; 21(1):863. PubMed ID: 38017538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis.
    Marima R; Hull R; Penny C; Dlamini Z
    Mutat Res Rev Mutat Res; 2021; 787():108376. PubMed ID: 34083040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradation.
    Li Y; Li L; Chen M; Yu X; Gu Z; Qiu H; Qin G; Long Q; Fu X; Liu T; Li W; Huang W; Shi D; Kang T; Luo M; Wu X; Deng W
    Mol Oncol; 2018 Mar; 12(3):391-405. PubMed ID: 29360267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the mitotic checkpoint gene MAD2L2 has prognostic significance in colon cancer.
    Rimkus C; Friederichs J; Rosenberg R; Holzmann B; Siewert JR; Janssen KP
    Int J Cancer; 2007 Jan; 120(1):207-11. PubMed ID: 17044027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic feature of mitotic arrest deficient 2-like protein 2 (MAD2L2) and structural basis for its interaction with chromosome alignment-maintaining phosphoprotein (CAMP).
    Hara K; Taharazako S; Ikeda M; Fujita H; Mikami Y; Kikuchi S; Hishiki A; Yokoyama H; Ishikawa Y; Kanno SI; Tanaka K; Hashimoto H
    J Biol Chem; 2017 Oct; 292(43):17658-17667. PubMed ID: 28887307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDH1 binds MAD2L2 in a Rev1-like pattern.
    Pernicone N; Grinshpon S; Listovsky T
    Biochem Biophys Res Commun; 2020 Oct; 531(4):566-572. PubMed ID: 32811646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDA-MB-157 Cell Line Presents High Levels of MAD2L2 and Dysregulated Mitosis.
    Pernicone N; Peretz L; Grinshpon S; Listovsky T
    Anticancer Res; 2020 Oct; 40(10):5471-5480. PubMed ID: 32988869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin promotes siMAD2L2‑induced apoptosis in colon cancer cells.
    Ma L; Li X; Zhao X; Sun H; Kong F; Li Y; Sui Y; Xu F
    Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAD2L2 dimerization and TRIP13 control shieldin activity in DNA repair.
    de Krijger I; Föhr B; Pérez SH; Vincendeau E; Serrat J; Thouin AM; Susvirkar V; Lescale C; Paniagua I; Hoekman L; Kaur S; Altelaar M; Deriano L; Faesen AC; Jacobs JJL
    Nat Commun; 2021 Sep; 12(1):5421. PubMed ID: 34521823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5' end resection.
    Boersma V; Moatti N; Segura-Bayona S; Peuscher MH; van der Torre J; Wevers BA; Orthwein A; Durocher D; Jacobs JJL
    Nature; 2015 May; 521(7553):537-540. PubMed ID: 25799990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the WNT/β-catenin/ZKSCAN3 Pathway in Regulating Chromosomal Instability in Colon Cancer Cell lines and Tissues.
    Cho YE; Kim JH; Che YH; Kim YJ; Sung JY; Kim YW; Choe BG; Lee S; Park JH
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion.
    Johnson EL; Singh R; Singh S; Johnson-Holiday CM; Grizzle WE; Partridge EE; Lillard JW
    World J Surg Oncol; 2010 Jul; 8():62. PubMed ID: 20649989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer.
    Thériault BL; Pajovic S; Bernardini MQ; Shaw PA; Gallie BL
    Int J Cancer; 2012 Apr; 130(8):1844-54. PubMed ID: 21618518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel LncRNA ZFHX4-AS1 as a Potential Prognostic Biomarker That Affects the Immune Microenvironment in Ovarian Cancer.
    Wang X; Wang Y; Sun F; Xu Y; Zhang Z; Yang C; Zhang L; Lou G
    Front Oncol; 2022; 12():945518. PubMed ID: 35903691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical significance and biological function of lncRNA SOCAR in serous ovarian carcinoma.
    Guo Q; Wang L; Zhu L; Lu X; Song Y; Sun J; Wu Z; Shi J; Wang Z; Zhou X
    Gene; 2019 Sep; 713():143969. PubMed ID: 31299360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. H4K20me2 distinguishes pre-replicative from post-replicative chromatin to appropriately direct DNA repair pathway choice by 53BP1-RIF1-MAD2L2.
    Simonetta M; de Krijger I; Serrat J; Moatti N; Fortunato D; Hoekman L; Bleijerveld OB; Altelaar AFM; Jacobs JJL
    Cell Cycle; 2018; 17(1):124-136. PubMed ID: 29160738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAD2L2 Promotes Open Chromatin in Embryonic Stem Cells and Derepresses the Dppa3 Locus.
    Rahjouei A; Pirouz M; Di Virgilio M; Kamin D; Kessel M
    Stem Cell Reports; 2017 Apr; 8(4):813-821. PubMed ID: 28330620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Fang L; Wang H; Li P
    Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.